Please upgrade your browser.
A key theme at this yearâs American Society of Clinical Oncology (ASCO) Annual Meeting was the use of a treatment rationale based on driver mutations and immunotherapy approaches that have potential in multiple tumor types.
Pfizer Inc said its kidney cancer drug did not meet the main goal of showing a statistically significant improvement in survival in a late-stage trial without the cancer getting worse.
Active surveillance of small kidney masses is a safe and effective alternative to immediate surgery, with similar overall and cancer specific survival rates, according to a study published in the November issue of the urology journal BJUI.
Professor Tim Eisen from Addenbrooke's Oncology Centre, Cambridge, talks to ecancer TV with Dr Bernard Escudier from Institut Gustave Roussy, France, Dr Thomas Powles from St Bartholomew Hospital, London, and Dr Thomas Hutson from Baylor Sammons Cancer Center, USA. The experts outline results from the major studies reporting at ESMO 2012 in mRCC.
WILEX AG announces results of Phase III ARISER study with RENCAREXÂ® in clear cell renal cell carcinoma
Trial did not meet its primary endpoint of median disease-free survival (DFS)
The authors believe they have discovered why obese cancer patients usually have poorer prognoses compared to slim people.
Feasibility of differential diagnosis of kidney tumors by comparative genomic hybridization of fine needle aspiration biopsies
The association of a genetic analysis that could improve the diagnostic accuracy of renal cell tumors in biopsy samples would allow better-informed therapeutic decisions.
The NCCN Oncology Research Program (ORP) announces funding of five new investigator-initiated studies of tivozanib as a result of funding through the AVEO/Astellas collaboration.
A new therapeutic vaccine 15 years in the making could make cancer kill itself.
Argos Therapeutics Identifies Immune Response Marker Connected to Prolonged Overall Survival in mRCC Patients Treated With AGS-003
Updated Immune Analysis From Phase 2 Clinical Trial Presented at 2012 Markers in Cancer Meeting
|Powered by NeonCRM|